Lithera Reports Positive Clinical Study Results From Its Phase 2b RESET Trial for LIPO-202, a Novel Treatment for Abdominal Body Contouring

September 30, 2013

LIPO-202, a novel, physician-administered, injectable pharmaceutical product designed to produce localized flattening of the abdominal treatment area through the non-ablative reduction of subcutaneous fat.
More »

Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

September 26, 2013

The submission is based on the entire data set from Durata Therapeutics' clinical development program, including positive results from two Phase 3 trials DISCOVER 1 and DISCOVER 2, as well as a previous Phase 3 study (VER-009).
More »

Dalbavancin Study Results to be Presented at IDWeek 2013

September 25, 2013

Durata (Nasdaq:DRTX) will present five posters on the company's lead IV antibiotic product candidate, dalbavancin, which is being clinically tested to treat patients with acute bacterial skin and skin structure infections (ABSSSI).
More »